{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T09:18:08Z","timestamp":1788427088783,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T00:00:00Z","timestamp":1710979200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["08-2008"],"award-info":[{"award-number":["08-2008"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005884","name":"Centro Nacional de Investigaciones Cardiovasculares Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005884","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.atherosclerosis.2024.117516","type":"journal-article","created":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T01:03:49Z","timestamp":1710551029000},"page":"117516","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Improved lipid-lowering treatment and reduction in cardiovascular disease burden in homozygous familial hypercholesterolemia: The SAFEHEART follow-up study"],"prefix":"10.1016","volume":"393","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8119-1245","authenticated-orcid":false,"given":"Rodrigo","family":"Alonso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Arroyo-Olivares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Luis","family":"D\u00edaz-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Fuentes-Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Arrieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raimundo","family":"de Andr\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Gonzalez-Bustos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Argueso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Martin-Ordiales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ceferino","family":"Martinez-Faedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e1tima","family":"Ill\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Saenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Donate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan F.","family":"Sanchez Mu\u00f1oz-Torrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Martinez-Hervas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Mata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2024.117516_bib1","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/eurheartj\/ehad197","article-title":"2023 update on European Atherosclerosis Society consensus statement on homozygous familial hypercholesterolaemia: new treatments and clinical guidance","volume":"44","author":"Cuchel","year":"2023","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2024.117516_bib2","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1016\/j.jacc.2020.03.057","article-title":"Worldwide prevalence of familial hypercholesterolemia: a meta-analyses of 11 million subjects","volume":"75","author":"Beheshti","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2024.117516_bib3","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.jacl.2016.04.006","article-title":"Clinical and molecular characteristics of homozygous familial hypercholesterolemia patients: insights from SAFEHEART registry","volume":"10","author":"Alonso","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2024.117516_bib4","first-page":"2508","article-title":"Phenotypical, clinical, and molecular aspects of adults and children with homozygous familial hypercholesterolemia in Iberoamerica","volume":"40","author":"Alves","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2024.117516_bib5","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/CIRCULATIONAHA.111.042523","article-title":"Reduction in mortality in subjects with homozygous familial Hypercholesterolemia associated with advances in lipid-lowering therapy","volume":"124","author":"Raal","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2024.117516_bib6","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.atherosclerosis.2015.09.029","article-title":"Improved cardiovascular outcomes following temporal advances in lipid-lowering therapy in a genetically-characterised cohort of familial hypercholesterolemia homozygotes","volume":"243","author":"Thompson","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2024.117516_bib7","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1093\/eurjpc\/zwab229","article-title":"Italian and European Working Group on Lomitapide in HoFH. Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan-European retrospective observational study","volume":"29","author":"D'Erasmo","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.atherosclerosis.2024.117516_bib8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2147\/CE.S174169","article-title":"Lomitapide: a review of its clinical use, efficacy, and tolerability","volume":"14","author":"Alonso","year":"2019","journal-title":"Core Evid."},{"key":"10.1016\/j.atherosclerosis.2024.117516_bib9","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2024.117516_bib10","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jacl.2012.03.004","article-title":"Apheresis in homozygous familial hypercholesterolemia: the results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia","volume":"6","author":"Graesdal","year":"2012","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2024.117516_bib11","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1007\/s12325-022-02131-3","article-title":"Is liver transplant Curative in homozygous familial hypercholesterolemia? A review of nine global cases","volume":"39","author":"Al Dubayee","year":"2022","journal-title":"Adv. Ther."},{"key":"10.1016\/j.atherosclerosis.2024.117516_bib12","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0140-6736(21)02001-8","article-title":"Homozygous familial hypercholesterolemia-worldwide experience","volume":"399","author":"Tromp","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2024.117516_bib13","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.jacasi.2023.07.011","article-title":"Clinical characteristics of homozygous familial hypercholesterolemia in Japan. A Survey using a National database","volume":"3","author":"Takeji","year":"2023","journal-title":"JACC Asia"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2024.117516_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2023.100309","article-title":"Homozygous familial hypercholesterolemia in Canada: an observational study","volume":"2","author":"Brown","year":"2023","journal-title":"JACC Adv"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.117516_bib15","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1476-511X-10-94","article-title":"Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish familial hypercholesterolemia Longitudinal cohort study (SAFEHEART)","volume":"10","author":"Mata","year":"2011","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.atherosclerosis.2024.117516_bib16","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1161\/CIRCGENETICS.116.001545","article-title":"Homozygous familiar hypercholesterolemia in Spain. Prevalence and phenotype-genotype relationship","volume":"9","author":"S\u00e1nchez-Hern\u00e1ndez","year":"2016","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.atherosclerosis.2024.117516_bib17","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.atherosclerosis.2017.04.002","article-title":"Mutational analysis and genotype-phenotype relation in familial hypercholesterolemia. The SAFEHEART Registry","volume":"262","author":"Bourbon","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2024.117516_bib18","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1161\/01.ATV.0000094410.66558.9A","article-title":"Genetics, clinical phenotype, and molecular cell biology of autosomal recessive hypercholesterolemia","volume":"23","author":"Soutar","year":"2003","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2024.117516_bib19","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.atherosclerosis.2020.08.027","article-title":"Homozygous familial Hypercholesterolemia in Italy: clinical and molecular features","volume":"312","author":"Bertoloni","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2024.117516_bib20","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.atherosclerosis.2016.03.009","article-title":"Phenotype diversity among patients with homozygous familial hypercholesterolemia: a cohort study","volume":"248","author":"Raal","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2024.117516_bib21","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/eurheartj\/ehu058","article-title":"Homozygous autosomal dominant hypercholesterolemia in The Netherlands: prevalence, genotype-phenotype relationship, and clinical outcomes","volume":"36","author":"Sjouke","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2024.117516_bib22","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.atherosclerosis.2017.01.015","article-title":"Long-term outcome in 53 patients with homozygous familial hypercholesterolemia in a single centre in France","volume":"257","author":"Bruckert","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2024.117516_bib23","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/eurheartj\/ehx317","article-title":"Survival in homozygous familial hypercholesterolemia is determined by the on-treatment level of serum cholesterol","volume":"39","author":"Thompson","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2024.117516_bib24","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jacl.2019.05.002","article-title":"A cross-national investigation of cardiovascular survival in homozygous familial hypercholesterolemia: the Sino-Roman study","volume":"13","author":"Stefanutti","year":"2019","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2024.117516_bib25","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/eurjpc\/zwab224","article-title":"Major adverse cardiovascular events in homozygous familial hypercholesterolemia: a systematic review and meta-analysis","volume":"29","author":"Kramer","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.atherosclerosis.2024.117516_bib26","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jacc.2019.12.020","article-title":"Long-term evolocumab in patients with familial hypercholesterolemia","volume":"75","author":"Santos","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2024.117516_bib27","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jacc.2020.05.027","article-title":"Efficacy and safety of alirocumab in adults with homozygous familial hypercholesterolemia: the ODYSSEY HoFH trial","volume":"76","author":"Blom","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2024.117516_bib28","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jacl.2020.08.006","article-title":"Long-term safety and efficacy of lomitapide in patients with homozygous familial hypercholesterolemia: five-year data from the Lomitapide Observational Worldwide Evaluation Registry (LOWER)","volume":"14","author":"Underberg","year":"2020","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2024.117516_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2023.100648","article-title":"The long-term efficacy and safety of Evinacumab in patients with homozygous familial hypercholesterolemia","volume":"2","author":"Raal","year":"2023","journal-title":"JACC adv"},{"key":"10.1016\/j.atherosclerosis.2024.117516_bib30","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.atherosclerosis.2018.08.020","article-title":"Familial hypercholesterolaemia patient support groups and advocacy: a multinational perspective","volume":"277","author":"Payne","year":"2018","journal-title":"Atherosclerosis"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915024000765?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915024000765?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T21:09:52Z","timestamp":1778706592000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915024000765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":30,"alternative-id":["S0021915024000765"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2024.117516","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improved lipid-lowering treatment and reduction in cardiovascular disease burden in homozygous familial hypercholesterolemia: The SAFEHEART follow-up study","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2024.117516","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"117516"}}